Adjuvant exemestane with ovarian suppression in premenopausal breast cancer

New England Journal of Medicine

Volumn 371, Issue 2, 2014, Pages 107-118

  Pagani, Olivia ^a   Regan, Meredith M ^e   Walley, Barbara A ^h   Fleming, Gini F ⁱ   Colleoni, Marco ^j   Láng, István ^p   Gomez, Henry L ^q   Tondini, Carlo ^l   Burstein, Harold J ^e   Perez, Edith A ^r   Ciruelos, Eva ^s   Stearns, Vered ^t   Bonnefoi, Hervé R ^u   Martino, Silvana ^v   Geyer Jr , Charles E ^w   Pinotti, Graziella ^m   Puglisi, Fabio ⁿ   Crivellari, Diana ^o   Ruhstaller, Thomas ^b   Winer, Eric P ^e   Rabaglio Poretti, Manuela ^c,d   Maibach, Rudolf ^d   Ruepp, Barbara ^d   Giobbie Hurder, Anita ^f   Price, Karen N ^g   Bernhard, Jürg ^c,d   Luo, Weixiu ^f   Ribi, Karin ^d   Viale, Giuseppe ^k   Coates, Alan S ^x   Gelber, Richard D ^g   Goldhirsch, Aron ^j   Francis, Prudence A ^y   more..

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d International Breast Cancer Study Group Coordinating Center   (Switzerland)

^e HARVARD MEDICAL SCHOOL   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^h TOM BAKER CANCER CENTRE   (Canada)

ⁱ UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^j EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^k UNIVERSITY OF MILAN   (Italy)

^l PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^m OSPEDALE DI CIRCOLO   (Italy)

ⁿ UNIVERSITY HOSPITAL OF UDINE   (Italy)

^o CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^p NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^q INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^r MAYO CLINIC   (United States)

^s HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^t JOHNS HOPKINS UNIVERSITY   (United States)

^u UNIVERSITÉ DE BORDEAUX   (France)

^v Angeles Clinic and Research Institute   (United States)

^w VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^x UNIVERSITY OF SYDNEY   (Australia)

^y UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; EXEMESTANE; TAMOXIFEN; TRIPTORELIN;

ADJUVANT THERAPY; ADULT; ALLERGIC REACTION; ARTHRALGIA; ARTICLE; BONE PAIN; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BREAST CANCER; CANCER SURVIVAL; DEPRESSION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPAREUNIA; ENDOMETRIUM CANCER; FATIGUE; FEMALE; FOLLOW UP; FRACTURE; GLUCOSE INTOLERANCE; GYNECOLOGIC CANCER; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HORMONE INHIBITION; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPERTENSION; INJECTION SITE REACTION; INSOMNIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MIDDLE AGED; MUSCULOSKELETAL DISEASE; NAUSEA; OSTEOPOROSIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SWEATING; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; VAGINA DISCHARGE; VAGINAL DRYNESS;

ADULT; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ESTRADIOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MASTECTOMY; MIDDLE AGED; OSTEOPOROSIS; PREMENOPAUSE; QUALITY OF LIFE; TAMOXIFEN; TRIPTORELIN PAMOATE;

EID: 84903904384     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1404037     Document Type: Article

References (17)

1. Carlson RW, Allred DC, Anderson BO, et al. Breast cancer: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009;7:122-92.
2. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010;28:3784-96.
3. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013;24:2206-23.
4. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-29. (Pubitemid 46224240)
5. Colleoni M, Giobbie-Hurder A, Regan MM, et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011;29:1117-24.
6. The BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361:766-76.
7. Howell A, Crusick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
8. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559-70.
9. van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011;377:321-31.
10. Regan MM, Pagani O, Fleming GF, et al. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast 2013;22:1094-100.
11. Common Terminology Criteria for Adverse Events Version 3.0. (http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf.)
12. Bernhard J, Luo W, Ribi K, et al. Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC). J Clin Oncol 2014;32:557. abstract.
13. Regan MM, Neven P, Giobbie-Hurder A, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 2011;12:1101-8.
14. Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011;12:631-41.
15. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771-84.
16. Goss PE, Ingle JN, Pritchard KI, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 - a randomized controlled phase III trial. J Clin Oncol 2013;31:1398-404.
17. LHRH-agonists in Early Breast Cancer Overview Group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007;369:1711-23.